متلازمة زيلويغر
مراجع

↑  Brul, S; Westerveld, A; Strijland, A; Wanders, R J; Schram, A W; Heymans, H S; Schutgens, R B; van den Bosch, H; Tager, J M (1 Jun 1988). "Genetic heterogeneity in the cerebrohepatorenal (Zellweger) syndrome and other inherited disorders with a generalized impairment of peroxisomal functions. A study using complementation analysis". Journal of Clinical Investigation (بالإنجليزية). 81 (6): 1710–1715. DOI:10.1172/jci113510. ISSN:0021-9738. PMC:442615. PMID:2454948. Archived from the original on 2018-06-19.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: تنسيق PMC (link)
↑  Zellweger's syndrome at Who Named It?
↑  Wiedermann, H.-R. (1 May 1991). "Hans-Ulrich Zellweger". European Journal of Pediatrics (بالإنجليزية). 150 (7): 451–451. DOI:10.1007/BF01958418. ISSN:0340-6199. Archived from the original on 2018-06-19.
1 2 3 4 5 6 7 8 9 10 11 12  Braverman، Nancy E.؛ Raymond، Gerald V.؛ Rizzo، William B.؛ Moser، Ann B.؛ Wilkinson، Mark E.؛ Stone، Edwin M.؛ Steinberg، Steven J.؛ Wangler، Michael F.؛ Rush، Eric T. (2016-3). "Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines". Molecular genetics and metabolism. ج. 117 ع. 3: 313–321. DOI:10.1016/j.ymgme.2015.12.009. ISSN:1096-7192. PMC:5214431. PMID:26750748. مؤرشف من الأصل في 17 ديسمبر 2019. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ= (مساعدة)صيانة الاستشهاد: تنسيق PMC (link)
1 2 3  Steinberg، Steven J.؛ Dodt، Gabriele؛ Raymond، Gerald V.؛ Braverman، Nancy E.؛ Moser، Ann B.؛ Moser، Hugo W. (2006-12). "Peroxisome biogenesis disorders". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. ج. 1763 ع. 12: 1733–1748. DOI:10.1016/j.bbamcr.2006.09.010. ISSN:0167-4889. مؤرشف من الأصل في 2019-12-06. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ= (مساعدة)
↑  GeneReviews: Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum
↑  Krause, Cindy; Rosewich, Hendrik; Thanos, Melissa; Gärtner, Jutta (2006-11). "Identification of novel mutations inPEX2,PEX6,PEX10,PEX12, andPEX13in Zellweger spectrum patients". Human Mutation (بالإنجليزية). 27 (11): 1157–1157. DOI:10.1002/humu.9462. ISSN:1059-7794. Archived from the original on 2019-12-13. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ= (help)
↑  Raymond, G. V.; Watkins, P.; Steinberg, S.; Powers, J. (2009). Handbook of Neurochemistry and Molecular Neurobiology (بالإنجليزية). Springer, Boston, MA. pp. 631–670. DOI:10.1007/978-0-387-30378-9_26. ISBN:9780387303451. Archived from the original on 2018-06-22.
↑  Woliver, R. (2009). Alphabet Kids - From ADD to Zellweger Syndrome. London, UK: Jessica Kingsley.
↑  Online Mendelian Inheritance in Man (OMIM) Zellweger syndrome; ZS -214100
↑  Steinberg, S.; Chen, L.; Wei, L.; Moser, A.; Moser, H.; Cutting, G.; Braverman, N. (2004). "The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum". Molecular Genetics and Metabolism. 83 (3): 252–263. doi:10.1016/j.ymgme.2004.08.008. PMID 15542397.
↑  Yik, W. Y.; Steinberg, S. J.; Moser, A. B.; Moser, H. W.; Hacia, J. G. (2009). "Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders". Human Mutation. 30 (3): E467–E480. doi:10.1002/humu.20932. PMC 2649967 . PMID 19105186.
↑  Van Duyn, MA; Moser, AE; Brown FR, 3rd; et al. (August 1984). "The design of a diet restricted in saturated very long-chain fatty acids: therapeutic application in adrenoleukodystrophy". The American Journal of Clinical Nutrition. 40 (2): 277–84. doi:10.1093/ajcn/40.2.277. PMID 6465061.
↑  Brown FR, 3rd; Van Duyn, MA; Moser, AB; et al. (October 1982). "Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids". The Johns Hopkins medical journal. 151 (4): 164–72. PMID 7120720.
↑  Moser, AB; Borel, J; Odone, A; et al. (March 1987). "A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients". Annals of Neurology. 21 (3): 240–9. doi:10.1002/ana.410210305. PMID 2440378.
↑  Martinez, M (26 June 1992). "Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders". Brain Research. 583 (1–2): 171–82. doi:10.1016/s0006-8993(10)80021-6. PMID 1504825.
↑  Paker, AM; Sunness, JS; Brereton, NH; et al. (31 August 2010). "Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial". Neurology. 75 (9): 826–30. doi:10.1212/WNL.0b013e3181f07061. PMC 3013498 . PMID 20805528.
↑  Steinberg, S.; Dodt, G.; Raymond, G.; Braverman, N.; Moser, A.; Moser, H. (2006). "Peroxisome biogenesis disorders". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1763 (12): 1733–48. doi:10.1016/j.bbamcr.2006.09.010. PMID 17055079.